FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a medicinal agent used in arresting syndrome of systemic inflammatory response. Agent comprises, mg: diphosphopyridine nucleotide, 0.3-100 and inosine, 40.0-1200. Proposed medicinal agent can comprise additionally inhibitor of angiotensin-converting enzyme, mainly, lisinopril, 2.5-100 and cardiac glycoside, mainly, digoxin, 0.07-0.3. The new medicinal agent possesses the capacity for arresting syndrome of systemic inflammatory response being independently of etiology of its rise, and allows obtaining the expressed and stable curative effect for short times.
EFFECT: improved and valuable properties of medicinal agent.
5 cl, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND ARRESTING NECROTIC ALTERATIONS IN BODY TISSUE | 2005 |
|
RU2311180C2 |
| PHARMACEUTICAL FORMULATION FOR TREATING DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | 2012 |
|
RU2504375C1 |
| METHOD FOR REDUCING INFLAMMATORY HYPERACTIVATION OF NEUTROPHILS | 2020 |
|
RU2758536C1 |
| CARDIOTROPIC PREPARATION | 1991 |
|
RU2035908C1 |
| HIGH-STABLE PHARMACEUTICAL FORMULATION OF LYOPHILISATE OF 3-OXYPYRIDINE AND METHYLPYRIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | 2012 |
|
RU2504376C1 |
| METHOD FOR DETERMINING SENSITIVITY TO ANGIOTENSIN- TRANSFORMING ENZYME IN MYOCARDIAL INFARCTION PATIENTS | 1995 |
|
RU2125447C1 |
| METHOD FOR TREATING DOGS WITH DILATED CARDIOMYOPATHY COMPLICATED BY CONGESTIVE CARDIAC FAILURE | 2020 |
|
RU2762989C1 |
| ANTIHYPOXIC AGENT | 1994 |
|
RU2098085C1 |
| FOOD VITAMIN-MINERAL SUPPLEMENT | 2007 |
|
RU2335926C1 |
| METHOD OF PREVENTING ACUTE LUNG INJURY IN THE SURGICAL TREATMENT OF NON-SMALL CELL LUNG CANCER COMPLICATED BY AN INFLAMMATORY PROCESS | 2022 |
|
RU2801089C1 |
